According to a BBC News report earlier today, abiraterone acetate has been approved for use by National Health Service (NHS) patients with metastic, castration-resistant prostate cancer (mCRPC) in Northern Ireland. A decision about availability of the drug in Scotland is expected on August 13. Abiraterone is already available to NHS patients in England and in Wales.
Filed under: Management, Treatment Tagged: | abiraterone, access, UK
Search for new and
ongoing trials on the
CTAG PCa web site
This is good news for men in Northern Ireland, and hopefully the Scottish SMC will follow the rest of the UK. I think the SMC has been negotiating with the manufacturers to get a better deal on price as NICE did when they reconsidered approval for abiraterone.